Candel Therapeutics

Candel Therapeutics company information, Employees & Contact Information

Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). For more information, visit www.candeltx.com or contact us at info@candeltx.com.

Company Details

Employees
69
Founded
-
Address
117 Kendrick Street,
Phone
6179165445
Email
in****@****ltx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Needham, Massachusetts
Looking for a particular Candel Therapeutics employee's phone or email?

Candel Therapeutics Questions

News

Candel Therapeutics to Participate in Upcoming Investor Conferences in September - Yahoo Finance

Candel Therapeutics to Participate in Upcoming Investor Conferences in September Yahoo Finance

Candel Therapeutics, Inc. Announces Participation in Upcoming Investor Conferences - Quiver Quantitative

Candel Therapeutics, Inc. Announces Participation in Upcoming Investor Conferences Quiver Quantitative

Cancer Immunotherapy Developer Candel Therapeutics Announces Three Major Conference Presentations - Stock Titan

Cancer Immunotherapy Developer Candel Therapeutics Announces Three Major Conference Presentations Stock Titan

Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan

Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference Stock Titan

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - Sahm

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board Sahm

Candel Therapeutics CEO Paul Peter Tak to Present at Canaccord Genuity 45th Annual Growth Conference - Quiver Quantitative

Candel Therapeutics CEO Paul Peter Tak to Present at Canaccord Genuity 45th Annual Growth Conference Quiver Quantitative

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference Yahoo Finance

Top Candel Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant